GPT and Fever: The most common treatment-related AEs (incidence >30%) to atezolizumab placebo plus vemurafenib and cobimetinib are blood creatinine phosphokinase increased (44·8%), diarrhoea (46·6%), rash (40·9%), arthralgia (28·1%), pyrexia (26·0%), alanine aminotransferase increased (22·8%), and lipase increased (27·4%).